| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $3,470,563 | 21 | 100 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | 0 | $0 | 2 | $245,022 | $-245,022 |
| Owen Adams Catherine | Chief Executive Officer | 0 | $0 | 1 | $249,932 | $-249,932 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | 0 | $0 | 2 | $506,412 | $-506,412 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | 0 | $0 | 7 | $602,845 | $-602,845 |
| Daly James M | director | 0 | $0 | 1 | $670,983 | $-670,983 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 0 | $0 | 8 | $1.2M | $-1.2M |
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, …
Over the last 12 months, insiders at Acadia Pharmaceuticals Inc. have bought $0 and sold $3.47M worth of Acadia Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Acadia Pharmaceuticals Inc. have bought $30.16M and sold $3.49M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 294,154 shares for transaction amount of $7.45M was made by BAKER BROS. ADVISORS LP () on 2023‑05‑24.
| 2026-10-30 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 3,321 0.002% | $20.88 | $69,342 | -0.34% | |
| 2026-08-06 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 14,292 0.0086% | $29.22 | $417,604 | -7.20% | |
| 2026-08-05 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 5,849 0.0034% | $29.00 | $169,638 | -8.30% | |
| 2026-07-30 | Sale | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | 16,558 0.0095% | $26.13 | $432,663 | -0.53% | |
| 2026-06-26 | Sale | Kihara James | PRINCIPAL ACCOUNTING OFFICER | 11,421 0.0069% | $26.08 | $297,912 | +1.97% | |
| 2026-05-26 | Sale | Kihara James | PRINCIPAL ACCOUNTING OFFICER | 5,401 0.0032% | $21.18 | $114,393 | +18.77% | |
| 2026-05-04 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 3,506 0.002% | $21.79 | $76,396 | +5.27% | |
| 2026-05-04 | Sale | Kihara James | PRINCIPAL ACCOUNTING OFFICER | 1,332 0.0008% | $21.79 | $29,024 | +5.27% | |
| 2026-04-07 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2,709 0.0016% | $22.20 | $60,140 | +0.81% | |
| 2026-04-07 | Sale | Kihara James | PRINCIPAL ACCOUNTING OFFICER | 1,030 0.0006% | $22.20 | $22,866 | +0.81% | |
| 2026-03-26 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 3,208 0.0019% | $21.65 | $69,456 | +3.59% | |
| 2026-03-26 | Sale | Kihara James | PRINCIPAL ACCOUNTING OFFICER | 1,109 0.0007% | $21.65 | $24,011 | +3.59% | |
| 2026-03-25 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 4,177 0.0024% | $21.47 | $89,680 | +0.95% | |
| 2026-03-25 | Sale | Kihara James | PRINCIPAL ACCOUNTING OFFICER | 833 0.0005% | $21.47 | $17,885 | +0.95% | |
| 2026-03-25 | Sale | Owen Adams Catherine | Chief Executive Officer | 11,641 0.0067% | $21.47 | $249,932 | +0.95% | |
| 2026-03-25 | Sale | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | 3,844 0.0022% | $21.47 | $82,531 | +0.95% | |
| 2026-03-25 | Sale | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | 3,435 0.002% | $21.47 | $73,749 | +0.95% | |
| 2026-02-09 | Sale | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | 6,950 0.0041% | $23.38 | $162,491 | -4.13% | |
| 2025-11-18 | Sale | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 10,262 0.006% | $23.69 | $243,114 | -1.01% | |
| 2025-11-18 | Sale | Kihara James | PRINCIPAL ACCOUNTING OFFICER | 4,084 0.0024% | $23.69 | $96,754 | -1.01% |
| BAKER BROS. ADVISORS LP | 39058564 22.6682% | $803.43M | 16 | 0 | +14.48% | |
| 14159, L.P. | 20278008 11.7686% | $417.12M | 1 | 0 | +3.15% | |
| BAKER FELIX | 18001203 10.4473% | $370.28M | 4 | 0 | +58.48% | |
| OXFORD BIOSCIENCE PARTNERS IV LP | 10 percent owner | 3160238 1.8341% | $65.01M | 2 | 0 | +29.7% |
| WALTON ALAN G | 2573836 1.4938% | $52.94M | 1 | 0 | +11.11% | |
| van Osch Martien | director | 1168892 0.6784% | $24.04M | 2 | 0 | +29.7% |
| GORDON CARL L | director | 774006 0.4492% | $15.92M | 2 | 0 | +29.7% |
| Hacksell Uli | CEO | 115549 0.0671% | $2.38M | 1 | 22 | +11.11% |
| Iversen Leslie L | director | 36127 0.021% | $743,132.39 | 1 | 4 | |
| SOLAND DANIEL B | director | 10000 0.0058% | $205,700.00 | 2 | 0 | <0.0001% |
| HARRIGAN EDMUND | director | 1000 0.0006% | $20,570.00 | 1 | 0 | <0.0001% |
$104,428,685 | 44 | 22.55% | $3.78B | |
ACADIA Pharmaceuticals Inc. (ACAD) | $1,275,975,557 | 32 | 19.44% | $3.54B |
$151,136,640 | 31 | -1.41% | $3.95B | |
$5,066,938 | 27 | 26.38% | $3.7B | |
$169,745,779 | 25 | 31.94% | $4B |
| Increased Positions | 175 | +45.93% | 14M | +8.41% |
| Decreased Positions | 168 | -44.09% | 17M | -10.14% |
| New Positions | 53 | New | 4M | New |
| Sold Out Positions | 44 | Sold Out | 2M | Sold Out |
| Total Postitions | 388 | +1.84% | 167M | -1.73% |
| Baker Bros. Advisors Lp | $1.13M | 25.38% | 42.9M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $532,863.00 | 11.99% | 20.27M | -383,772 | -1.86% | 2025-09-30 |
| Vanguard Group Inc | $399,066.00 | 8.98% | 15.18M | -84,869 | -0.56% | 2025-09-30 |
| State Street Corp | $190,746.00 | 4.29% | 7.26M | +1M | +17.44% | 2025-09-30 |
| Rtw Investments, Lp | $187,830.00 | 4.23% | 7.14M | -2M | -20.58% | 2025-09-30 |
| Geode Capital Management, Llc | $82,357.00 | 1.85% | 3.13M | +108,547 | +3.59% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $73,563.00 | 1.66% | 2.8M | +402,534 | +16.8% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $65,308.00 | 1.47% | 2.48M | +2M | +311.42% | 2025-09-30 |
| Palo Alto Investors Lp | $64,849.00 | 1.46% | 2.47M | -96,525 | -3.77% | 2025-09-30 |
| Braidwell Lp | $62,535.00 | 1.41% | 2.38M | +2M | New | 2025-09-30 |